BRAF and neoplasm: Regorafenib (Grothey et al., 2013), an oral multikinase inhibitor, inhibits angiogenesis (VEGFR 1–3 and Tie2), tumorigenesis (KIT, RET, RAF1, and BRAF), and the tumor microenvironment (platelet-derived and fibroblast growth factor receptors), which leads to suppression inhibition of tumorigenesis, tumor neovascularization, and maintenance of tumor microenvironment signaling.